ECE2024 Eposter Presentations Endocrine-Related Cancer (90 abstracts)
99mTechnetium-labeled GRPR antagonist for the imaging of prostate cancer – first clinical images
Barbara Bromińska 1 , Berthold A. Nock 2 , Theodosia Maina 2 , Aikaterini Kaloudi 2 , Panagiotis Kanellopoulos 2 , Barbara Janota 3 , Renata Mikołajczak 3 , Marek Ruchała 1 & Rafał Czepczyński 1
1Poznan University of Medical Sciences, Department of Endocrinology, Metabolism and Internal Diseases, Poznań, Poland; 2Molecular Radiopharmacy, INRaSTES, NCSR ‘Demokritos’, Athens, Greece; 3National Centre for Nuclear Research, Radioisotope Centre Polatom, Otwock-Świerk, Poland
Introduction: Nuclear medicine procedures offer a possibility of tracing tumor cells based on their physiology. Gastrin-Releasing Peptide receptor (GRPr) is aberrantly expressed in numerous cancers, among them prostate cancer. Demobesin-15 ([99mTc]DB15) is a novel GRPR-antagonist designed for the evaluation of GRPr expression in different tumors. It has been shown to accumulate in animal prostate cancer models. Hereby, we present our experiences with the first in-human use of [99mTc]Tc-DB15 SPECT/CT in PCa patients.
Materials and Methods: We qualified three male patients with a newly diagnosed PCa for the study. Diagnosis was based on the prostate biopsy. There were no metastases or extra prostatic extension in any of the patients. All of the patients agreed to participate in the research and gave their informed consent. Firstly, [99mTc]Tc-DB15 SPECT/CT was performed followed by [18F]-choline PET/CT that served as a reference method. Patients were observed for adverse events directly after injection of the tracer and laboratory measurements were recorded over 28 days.
Results: In all three patients, moderate focal [99mTc]Tc-DB15 focal uptake in the prostate was visible at planar and pelvic SPECT/CT images. No foci of increased [99mTc]Tc-DB15 uptake outside the gland was observed. In the PET/CT images of the prostate showed increased 18F-choline accumulation in the same areas of the gland as depicted in [99mTc]Tc-DB15 SPECT/CT scans. PET/CT did not show any sign of extra prostatic extension of the cancer, nor metastases. We did not record any adverse events post injection of [99mTc]Tc-DB15.
Conclusions: Accumulation of [99mTc]Tc-DB15 in the PCa tissue provides preliminary evidence for the utility of this modality in the in vivo detection of GRPr expression in the tumor. What is important, we did not notice any side effects, thus confirming biosafety of [99mTc]Tc-DB15. For confirmation of clinical utility of [99mTc]Tc-DB15 SPECT/CT in PCs further research should be conducted.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more